Back to Journals » OncoTargets and Therapy » Volume 3

Profile of temsirolimus in the treatment of advanced renal cell carcinoma

Authors Staehler M, Haseke N, Khoder W, Stief CG

Published 15 September 2010 Volume 2010:3 Pages 191—196

DOI https://doi.org/10.2147/OTT.S7657

Review by Single-blind

Peer reviewer comments 5


Michael Staehler, Nicolas Haseke, Wael Khoder, Christian G Stief
Department of Urology, University of Munich, Klinikum Grosshadern, Germany

Abstract: Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trial temsirolimus has shown an overall survival benefit for patients with metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk mRCC patients. We discuss the indication, side effects and clinical implications of temsirolimus treatment.

Keywords: renal cell cancer, non-clear cell renal cancer, temsirolimus, first-line therapy, overall survival, nephrectomy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]